- Home
- A-Z Publications
- Current Pharmaceutical Biotechnology
- Previous Issues
- Volume 4, Issue 3, 2003
Current Pharmaceutical Biotechnology - Volume 4, Issue 3, 2003
Volume 4, Issue 3, 2003
-
-
Application of Microbial Biotransformation for the New Drug Discovery Using Natural Drugs as Substrates
Authors: R.K. Venisetty and V. CiddiThis review describes microbial transformation studies of natural drugs, its importance in correlating them with the corresponding metabolism (biotransformation) in animal system and in the structural modification of complex drug molecules, which are difficult to obtain synthetically. Emphasis is laid on the potential microorganisms, which mimic the pathways of mammalian metabolism and which involve in stereosele Read More
-
-
-
Hepatitis C Virus Clearance: The Enigma of Failure Despite an Impeccable Survival Strategy
More LessInfection with human hepatitis C virus (HCV) as a result of a bilateral process of host-virus interactions. There are factors on both sides that contribute to clearance and to chronicity. Virus strategy to survive is built on several basic features. The first, recently recognized, is a wide cell tropism. HCV can infect not only hepatocytes, but also cells of immune system (B-cells, monocytes, macrophages, dendritic cells), epith Read More
-
-
-
Host Background Factors Contributing to Hepatitis C Virus Clearance
Authors: M.G. Isaguliants and N.N. OzeretskovskayaThis review is an attempt to characterize the host in the earliest events of hepatitis C virus (HCV) infection before the on-set of adaptive immune response. Host meets the replicating HCV with innate immune response in the form of proinflammatory cytokine production, activation of natural killer (NK), NKT and dendritic cells. The potency of innate response is shaped by a wide panel of genetically predetermined constants an Read More
-
-
-
Invasive and Non-invasive Monitoring of Hepatitis C Virus-Induced Liver Fibrosis: Alternatives or Complements?
Authors: O. Olga and D. NikolaiChronic hepatitis C virus (HCV) infection results in the development of liver fibrosis and cirrhosis in 20 to 25% of patients. The main task of the physician when examining a patient with a verified HCV infection is to identify the activity of inflammatory and necrotic processes in the liver, as well as the stage of fibrosis, and the reversibility of detected changes. Along with other clinical and laboratory parameters, this plays a Read More
-
-
-
Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Authors: A. Evangeliou and D. VlassopoulosCarnitine is an ammo acid derivative found in high energy demanding tissues (skeletal muscles, myocardium, the liver and the suprarenal glands). It is essential for the intermediary metabolism of fatty acids. Carnitine is indispensable for β-oxidation of long-chain fatty acids in the mitochondria but also regulates CoA concentration and removal of the produced acyl groups. AcylCoAs act as restraining factor for several enzymes Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cpb
Journal
10
5
false
en
